BMS’s Camzyos shows continued benefit in paediatric oHCM at 56 weeks
Bristol Myers Squibb (BMS) has reported longer-term data from its Phase III clinical trial assessing Camzyos (mavacamten) in paediatric patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The late-breaker data were presented at the …